IP Library › Granted Patent US 12,637,516
Granted Patent B2
US 12,637,516 · App. 17/951,774 · Granted May 26, 2026

BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof

Inventors: Yutian Wei (Hong Kong, CN); Lin Zhu (Hong Kong, CN); Yanfeng Li (Hong Kong, CN); Yihong Yao (Rockville, MD); Xin Yao (Rockville, MD); Jiaqi Huang (Rockville, MD); Li Zhang (Hong Kong, CN); Shigui Zhu (Rockville, MD); Xiaoteng Lv (Hong Kong, CN)
Assignee: Shanghai AbelZeta Ltd.
C07K16/2878A61K40/11A61K40/31A61K40/4215A61P35/00C07K14/7051C12N5/0636C12N5/0638A61K2239/31A61K2239/38A61K2239/48C07K2319/02C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,637,516
App. No.
17/951,774
Granted
May 26, 2026
Kind
B2
Abstract

The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

Claims (45)

1 . A nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-BCMA antigen binding region which comprises: (i) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 1, and (ii) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 2;

wherein V L is located at the N-terminus of V H ,

wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA,

wherein the CAR further comprises:

(a) a signal peptide having an amino acid sequence set forth in SEQ ID NO: 9,

(b) a hinge region having an amino acid sequence set forth in SEQ ID NO: 12,

(c) a transmembrane domain having an amino acid sequence set forth in SEQ ID NO: 13,

(d) a co-stimulatory region having an amino acid sequence set forth in SEQ ID NO: 14, and

(e) a cytoplasmic signaling domain having an amino acid sequence set forth in SEQ ID NO: 15.

2 . A vector comprising a nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-BCMA antigen binding region which comprises: (i) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 1, and (ii) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 2;

wherein V L is located at the N-terminus of V H ,

wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA,

wherein the CAR further comprises:

(a) a signal peptide having an amino acid sequence set forth in SEQ ID NO: 9,

(b) a hinge region having an amino acid sequence set forth in SEQ ID NO: 12,

(c) a transmembrane domain having an amino acid sequence set forth in SEQ ID NO: 13,

(d) a co-stimulatory region having an amino acid sequence set forth in SEQ ID NO: 14, and

(e) a cytoplasmic signaling domain having an amino acid sequence set forth in SEQ ID NO: 15.

3 . A pharmaceutical composition comprising a vector, wherein the vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-BCMA antigen binding region which comprises: (i) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 1, and (ii) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 2;

wherein V L is located at the N-terminus of V H ,

wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA,

wherein the CAR further comprises:

(a) a signal peptide having an amino acid sequence set forth in SEQ ID NO: 9,

(b) a hinge region having an amino acid sequence set forth in SEQ ID NO: 12,

(c) a transmembrane domain having an amino acid sequence set forth in SEQ ID NO: 13,

(d) a co-stimulatory region having an amino acid sequence set forth in SEQ ID NO: 14, and

(e) a cytoplasmic signaling domain having an amino acid sequence set forth in SEQ ID NO: 15.

4 . An engineered T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-BCMA antigen binding region which comprises: (i) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 1, and (ii) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 2;

wherein V L is located at the N-terminus of V H ,

wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA,

wherein the CAR further comprises:

(a) a signal peptide having an amino acid sequence set forth in SEQ ID NO: 9,

(b) a hinge region having an amino acid sequence set forth in SEQ ID NO: 12,

(c) a transmembrane domain having an amino acid sequence set forth in SEQ ID NO: 13,

(d) a co-stimulatory region having an amino acid sequence set forth in SEQ ID NO: 14, and

(e) a cytoplasmic signaling domain having an amino acid sequence set forth in SEQ ID NO: 15.

5 . A pharmaceutical composition comprising an engineered T cell, wherein the engineered T cell comprises a nucleic acid encoding a chimeric antigen receptor (CAR), the CAR comprising an anti-BCMA antigen binding region which comprises: (i) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 1, and (ii) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 2;

wherein V L is located at the N-terminus of V H ,

wherein the anti-BCMA antigen-binding region is a single-chain variable fragment (scFv) that specifically binds BCMA,

wherein the CAR further comprises:

(a) a signal peptide having an amino acid sequence set forth in SEQ ID NO: 9,

(b) a hinge region having an amino acid sequence set forth in SEQ ID NO: 12,

(c) a transmembrane domain having an amino acid sequence set forth in SEQ ID NO: 13,

(d) a co-stimulatory region having an amino acid sequence set forth in SEQ ID NO: 14, and

(e) a cytoplasmic signaling domain having an amino acid sequence set forth in SEQ ID NO: 15.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67128 FRAME: 44. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 7, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067334/0083 →
CHANGE OF NAME Recorded Apr 16, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067128/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: CELLULAR BIOMEDICINE GROUP HK LIMITED
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 061815/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: WEI, YUTIAN; ZHU, LIN; LI, YANFENG; YAO, YIHONG; YAO, XIN; HUANG, JIAQI; ZHANG, LI; ZHU, SHIGUI; LV, XIAOTENG
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 061535/0493 →
Priority Claims (1)
CN 201810326346.9 · Apr 12, 2018 · national
Continuity (4)
Continuation 17476661 · Sep 16, 2021
Continuation 16881668 · May 22, 2020
Continuation In Part PCTCN2019081064 · Apr 2, 2019
Related Publication 20230053305A1 · Feb 16, 2023
References Cited (16)
US 11142581B2 · Wei · 2021 [cited by examiner]
US 11498973B2 · Wei · 2022 [cited by examiner]
US 20200261501A1 · Quigley et al. · 2020 [cited by applicant]
KR 1020140105757A · 2014 [cited by applicant]
WO 2019232503A1 · 2019 [cited by applicant]
WO 2020025596A1 · 2020 [cited by applicant]
Cohen et al. “B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study.” Blood 128.22 (2016): 1147 (Year: 2016). [cited by examiner]
International Search Report and Written Opinion in PCT/US21/61410, mailed Mar. 30, 2022. [cited by applicant]
Berahovich et al. “CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth”, Cancers, 2018, vol. 10, No. 9, 323 [16 pages]. [cited by applicant]
Bernabei et al. “PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed Car T Cells”, Blood, vol. 132 (Supplement 1), 2018, p. 1973 [4 pages… [cited by applicant]
Feng et al. “Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma”, Scandinavian Journal of Immunology, vol. 92, No. 2, 2020, e12910, pp. 109-119. [11 pages]. [cited by applicant]
Madduri et al. “CARTITUDE-1:Phase 1 b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma”, 62nd ASH Annual Meetin… [cited by applicant]
MAILANKODY. “Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed Car T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study … [cited by applicant]
Metelo et al. “Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups”, Blood, vol. 134 (Supplement 1), 2019: 1834 [3 pages]. [cited by applicant]
Munshi et al. “Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results”, Journal of Clinical Oncology, 2020,… [cited by applicant]
Rosenberg et al. “Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma”, New Eng. J. of Med. 319: 1676, 1988. [ 5 pages]. [cited by applicant]